The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).
 
Mao Uematsu
No Relationships to Disclose
 
Yoko Tsukita
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Daiichi Sankyo Pharmaceutical; Lilly O.; MSD; Taiho Pharmaceutical
 
Takehiro Tozuka
Honoraria - AstraZeneca/Hong Kong; Chugai Pharma
 
Kohei Kushiro
Employment - Takeda (I)
Speakers' Bureau - AstraZeneca; Chugai Pharma; Kyowa Kirin; Merck
 
Shinobu Hosokawa
Speakers' Bureau - AstraZeneca Japan; Bristol Myers Squibb K.K.; Chugai Pharma; Ono Pharmaceutical
 
Toshiyuki Sumi
Speakers' Bureau - Ono Pharmaceutical
 
Osamu Honjo
No Relationships to Disclose
 
Ou Yamaguchi
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; Ono Pharmaceutical
 
Tetsuhiko Asao
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Merck; Merck Serono; MSD K.K; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Nippon Boehringer Ingelheim
 
Jun Sugisaka
No Relationships to Disclose
 
Go Saito
Speakers' Bureau - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Jun Shiihara
No Relationships to Disclose
 
Ryo Morita
No Relationships to Disclose
 
Seigo Katakura
No Relationships to Disclose
 
Takehiro Yasuda
Honoraria - AstraZeneca; Chugai Pharma; Nippon Kayaku; Ono Pharmaceutical; Sanofi
 
Kakeru Hisakane
No Relationships to Disclose
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Lilly Japan; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Otsuka; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo KK; Lilly; Merck
Research Funding - Chugai Pharma (Inst); Lilly (Inst)
 
Satoshi Morita
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Company; Chugai Pharma; Eisai; Lilly Japan; MSD K.K.; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Pfizer
Research Funding - Eisai (Inst)
 
Kunihiko Kobayashi
Speakers' Bureau - AstraZeneca; Takeda
 
Hajime Asahina
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Kyowa Hakko Kirin; Lilly; Merck; MSD; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca